Oncology

A total of 32% of registered nurses and 29% of infusion nurses reported that educating patients regarding their diseases was challenging.

The study found that older females with central nervous system tumors had significantly lower vigorous physical activity participation vs their counterparts.

Bevacizumab-nwgd was assessed to be comparable to bevacizumab based on a submission showing pharmacokinetic, efficacy, safety, and immunogenicity data.

Data from the LOXO-TRK-14001, SCOUT, and NAVIGATE trials support the full approval of larotrectinib in NTRK gene fusion-positive tumors.

Quality of life improvements can be made if clinicians better understand auditory attention decay after cancer treatment in pediatric patients with cerebellar tumors.

The International Psycho-Oncology Society announced the first-ever WPOD on April 9, 2025, to bring more focus to psychosocial care in cancer therapy.

It is crucial that oncologists and other cancer care specialists collaborate with psycho-oncology specialists to optimize patient treatment outcomes.

World Psycho-Oncology Day is an initiative aimed at spreading awareness and pursuing the further integration of psychosocial care into cancer treatment.

Organizations such as ASCO and ESMO recognize the importance of integrating psychosocial care into cancer treatment.

The ESMO Precision Oncology Working Group recommendations can serve as guidance to define standards for MTBs to integrate precision oncology into practice.

Most patients with cancer who took part in a telehealth group expressed that they liked the members of their group and felt less social isolation.

Data from the phase 3 CheckMate-67T trial support the CHMP’s recommendation for approving subcutaneous nivolumab across various solid tumor indications.

No dose-limiting toxicities were seen with solnerstotug in patients with PD-L1–resistant tumors, and most adverse effects were grades 1/2 in severity.

For Terri Lynn Shigle, PharmD, the field of hematology-oncology is deeply personal. Having lost loved ones to cancer, she was drawn to a career where she could make a meaningful difference in patient care.

In celebration of Women’s History Month, ASTCT is proud to highlight the inspiring journeys of women making a profound impact in transplantation and cellular therapy.

Collaboration among different medical and research institutions may help improve quality of care for patients with cancer exposed to climate disasters.

Recipients of hematopoietic stem cell transplantation may benefit from psychosocial interventions and supportive care following their procedure.

Phase 2 data may support atezolizumab plus chemotherapy as a treatment option in advanced or recurrent thymic carcinoma.

As artificial intelligence has arrived in the oncology field, experts discuss how this new technology can have implications for transforming clinical practice.

Learn how COVID-19 impacted oncology practice from the uptake of telehealth to delays in screening, with key takeaways from leading oncologists.

Based on positive safety data from the third cohort, a safety review committee approved the opening of a fourth cohort as well as more enrollment into the third cohort.

Leading multidisciplinary oncology professionals look back at how the COVID-19 pandemic changed cancer care.

Testing AI-powered tools globally across diverse patient groups may ensure that they are accurate and consistent for all patients.

Hear from leading cancer experts about the lasting impact the COVID-19 pandemic has left on clinical practice.

For International Women's Day, CancerNetwork highlights impactful oncology research on topics from rising health care costs to innovative treatments.

The FDA has approved 2 denosumab biosimilars for all prior approvals for the reference drugs in patients with cancers and osteoporosis.

AI-powered pathology imaging enables a more comprehensive assessment of tumor microenvironments than humans alone could perceive.

A retrospective cohort study found that, of Medicare decedents with advanced cancer, 45% experienced potentially aggressive end-of-life care.

Phase 2 study results revealed NP-G2-044 plus standard of care anti–PD-1 therapy indicated treatment exhibited responses across at least 7 cancer types.